secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001558370-23-019766
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure discontinues NC762, prioritizes LNCB74 ADC; NC410 data expected H1 2024
--------------------------------------------------------------------------------

- NC410 (LAIR-2 fusion) combination with pembrolizumab adding patients to 100 mg cohort for microsatellite stable colorectal cancer without liver mets; data expected H1 2024.
- NC762 (B7-H4 mAb) development halted due to competitive environment and limited activity; resources shifted to LNCB74 (B7-H4 ADC).
- LNCB74 set to initiate dose range-finding toxicology study and GMP manufacturing in early 2024.
- NC525 (LAIR-1 mAb) Phase 1a dose escalation ongoing (4th cohort enrolled); safe and well tolerated; data expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023019766/0001558370-23-019766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023019766/nxtc-20231214x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer